Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Review

The emerging role of ISWI chromatin remodeling complexes in cancer

Authors: Yanan Li, Han Gong, Pan Wang, Yu Zhu, Hongling Peng, Yajuan Cui, Heng Li, Jing Liu, Zi Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Disordered chromatin remodeling regulation has emerged as an essential driving factor for cancers. Imitation switch (ISWI) family are evolutionarily conserved ATP-dependent chromatin remodeling complexes, which are essential for cellular survival and function through multiple genetic and epigenetic mechanisms. Omics sequencing and a growing number of basic and clinical studies found that ISWI family members displayed widespread gene expression and genetic status abnormalities in human cancer. Their aberrant expression is closely linked to patient outcome and drug response. Functional or componential alteration in ISWI-containing complexes is critical for tumor initiation and development. Furthermore, ISWI-non-coding RNA regulatory networks and some non-coding RNAs derived from exons of ISWI member genes play important roles in tumor progression. Therefore, unveiling the transcriptional regulation mechanism underlying ISWI family sparked a booming interest in finding ISWI-based therapies in cancer. This review aims at describing the current state-of-the-art in the role of ISWI subunits and complexes in tumorigenesis, tumor progression, immunity and drug response, and presenting deep insight into the physiological and pathological implications of the ISWI transcription machinery in cancers.
Literature
1.
Wang Z, Wang P, Li Y, Peng H, Zhu Y, Mohandas N, et al. Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies. Signal Transduct Target Ther. 2021;6:24.PubMedPubMedCentralCrossRef
2.
Hota SK, Bruneau BG. ATP-dependent chromatin remodeling during mammalian development. Development (Cambridge, England). 2016;143:2882–97.CrossRef
3.
4.
5.
Erdel F, Schubert T, Marth C, Längst G, Rippe K. Human ISWI chromatin-remodeling complexes sample nucleosomes via transient binding reactions and become immobilized at active sites. Proc Natl Acad Sci U S A. 2010;107:19873–8.PubMedPubMedCentralCrossRef
6.
Ma Y, Liu X, Liu Z, Wei S, Shang H, Xue Y, et al. The chromatin remodeling protein Bptf promotes posterior neuroectodermal fate by enhancing Smad2-activated wnt8a expression. J Neurosci. 2015;35:8493–506.PubMedPubMedCentralCrossRef
7.
Judd J, Duarte FM, Lis JT. Pioneer-like factor GAF cooperates with PBAP (SWI/SNF) and NURF (ISWI) to regulate transcription. Genes Dev. 2021;35:147–56.PubMedPubMedCentralCrossRef
8.
Barisic D, Stadler MB, Iurlaro M, Schübeler D. Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. Nature. 2019;569:136–40.PubMedPubMedCentralCrossRef
9.
Aydin ÖZ, Marteijn JA, Ribeiro-Silva C, Rodríguez López A, Wijgers N, Smeenk G, et al. Human ISWI complexes are targeted by SMARCA5 ATPase and SLIDE domains to help resolve lesion-stalled transcription. Nucleic Acids Res. 2014;42:8473–85.PubMedPubMedCentralCrossRef
10.
11.
Oppikofer M, Sagolla M, Haley B, Zhang HM, Kummerfeld SK, Sudhamsu J, et al. Non-canonical reader modules of BAZ1A promote recovery from DNA damage. Nat Commun. 2017;8:862.PubMedPubMedCentralCrossRef
12.
Vidi PA, Liu J, Salles D, Jayaraman S, Dorfman G, Gray M, et al. NuMA promotes homologous recombination repair by regulating the accumulation of the ISWI ATPase SNF2h at DNA breaks. Nucleic Acids Res. 2014;42:6365–79.PubMedPubMedCentralCrossRef
13.
Klement K, Luijsterburg MS, Pinder JB, Cena CS, Del Nero V, Wintersinger CM, et al. Opposing ISWI- and CHD-class chromatin remodeling activities orchestrate heterochromatic DNA repair. J Cell Biol. 2014;207:717–33.PubMedPubMedCentralCrossRef
14.
Goodwin LR, Picketts DJ. The role of ISWI chromatin remodeling complexes in brain development and neurodevelopmental disorders. Mol Cell Neurosci. 2018;87:55–64.PubMedCrossRef
15.
Chioda M, Vengadasalam S, Kremmer E, Eberharter A, Becker PB. Developmental role for ACF1-containing nucleosome remodellers in chromatin organisation. Development. 2010;137:3513–22.PubMedCrossRef
16.
Mellor J, Morillon A. ISWI complexes in Saccharomyces cerevisiae. Biochim Biophys Acta. 2004;1677:100–12.PubMedCrossRef
17.
Bouazoune K, Brehm A. ATP-dependent chromatin remodeling complexes in Drosophila. Chromosom Res. 2006;14:433–49.CrossRef
18.
Corona DF, Siriaco G, Armstrong JA, Snarskaya N, McClymont SA, Scott MP, et al. ISWI regulates higher-order chromatin structure and histone H1 assembly in vivo. PLoS Biol. 2007;5:e232.PubMedPubMedCentralCrossRef
19.
Kwon SY, Xiao H, Glover BP, Tjian R, Wu C, Badenhorst P. The nucleosome remodeling factor (NURF) regulates genes involved in Drosophila innate immunity. Dev Biol. 2008;316:538–47.PubMedCrossRef
20.
Maier VK, Chioda M, Rhodes D, Becker PB. ACF catalyses chromatosome movements in chromatin fibres. EMBO J. 2008;27:817–26.PubMedCrossRef
21.
Witkowski L, Foulkes WD. In brief: picturing the complex world of chromatin remodelling families. J Pathol. 2015;237:403–6.PubMedCrossRef
22.
Oppikofer M, Bai T, Gan Y, Haley B, Liu P, Sandoval W, et al. Expansion of the ISWI chromatin remodeler family with new active complexes. EMBO Rep. 2017;18:1697–706.PubMedPubMedCentralCrossRef
23.
Dar AA, Nosrati M, Bezrookove V, de Semir D, Majid S, Thummala S, et al. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy. J Natl Cancer Inst. 2015;107:djv034.
24.
Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One. 2010;5:e9657.PubMedPubMedCentralCrossRef
25.
Hou Y-L, Chen H, Ge M-J, Li F-Z, Xue C-J, Wu Y-F, et al. Quantification of serum HBXAP DNA in lung cancer patients by quantitative fluorescent polymerase chain reaction. Mol Biol Rep. 2013;40:4091–6.PubMedCrossRef
26.
Pérez-Pena J, Páez R, Nieto-Jiménez C, Sánchez VC, Galan-Moya EM, Pandiella A, et al. Mapping Bromodomains in breast cancer and association with clinical outcome. Sci Rep. 2019;9:5734.PubMedPubMedCentralCrossRef
27.
Yasui K, Imoto I, Fukuda Y, Pimkhaokham A, Yang ZQ, Naruto T, et al. Identification of target genes within an amplicon at 14q12-q13 in esophageal squamous cell carcinoma. Genes, Chromosomes Cancer. 2001;32:112–8.PubMedCrossRef
28.
Gu L, Frommel SC, Oakes CC, Simon R, Grupp K, Gerig CY, et al. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nat Genet. 2015;47:22–30.PubMedCrossRef
29.
Pietrzak K, Kuzyakiv R, Simon R, Bolis M, Bär D, Aprigliano R, et al. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN-loss. Proc Natl Acad Sci U S A. 2020;117:3637–47.
30.
Dai M, Lu J-J, Guo W, Yu W, Wang Q, Tang R, et al. BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas. Oncotarget. 2015;6:33878–92.PubMedPubMedCentralCrossRef
31.
Dai M, Hu S, Liu C-F, Jiang L, Yu W, Li Z-L, et al. BPTF cooperates with p50 NF-κB to promote COX-2 expression and tumor cell growth in lung cancer. Am J Transl Res. 2019;11:7398–409.PubMedPubMedCentral
32.
Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, et al. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun. 2016;7:12451.PubMedPubMedCentralCrossRef
33.
Mayes K, Elsayed Z, Alhazmi A, Waters M, Alkhatib SG, Roberts M, et al. BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. Oncotarget. 2017;8:64344–57.PubMedPubMedCentralCrossRef
34.
Koedoot E, Fokkelman M, Rogkoti V-M, Smid M, van de Sandt I, de Bont H, et al. Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes. Nat Commun. 2019;10:2983.PubMedPubMedCentralCrossRef
35.
Ye Y, Xiao Y, Wang W, Wang Q, Yearsley K, Wani AA, et al. Inhibition of expression of the chromatin remodeling gene, SNF2L, selectively leads to DNA damage, growth inhibition, and cancer cell death. Mol Cancer Res. 2009;7:1984–99.PubMedCrossRef
36.
Takeshima H, Niwa T, Takahashi T, Wakabayashi M, Yamashita S, Ando T, et al. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer Lett. 2015;357:328–38.PubMedCrossRef
37.
Eckey M, Kuphal S, Straub T, Rümmele P, Kremmer E, Bosserhoff AK, et al. Nucleosome remodeler SNF2L suppresses cell proliferation and migration and attenuates Wnt signaling. Mol Cell Biol. 2012;32:2359–71.PubMedPubMedCentralCrossRef
38.
Xia P, Wang S, Huang G, Zhu P, Li M, Ye B, et al. WASH is required for the differentiation commitment of hematopoietic stem cells in a c-Myc-dependent manner. J Exp Med. 2014;211:2119–34.PubMedPubMedCentralCrossRef
39.
Zhu P, Wang Y, He L, Huang G, Du Y, Zhang G, et al. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest. 2015;125:3795–808.PubMedPubMedCentralCrossRef
40.
Lazzaro MA, Picketts DJ. Cloning and characterization of the murine imitation switch (ISWI) genes: differential expression patterns suggest distinct developmental roles for Snf2h and Snf2l. J Neurochem. 2001;77:1145–56.PubMedCrossRef
41.
Jin Q, Mao X, Li B, Guan S, Yao F, Jin F. Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer. Tumour Biol. 2015;36:1895–902.PubMedCrossRef
42.
Sheu JJ-C, Choi JH, Yildiz I, Tsai F-J, Shaul Y, Wang T-L, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res. 2008;68:4050–7.PubMedPubMedCentralCrossRef
43.
Wang Y, Qin J, Liu Q, Hong X, Li T, Zhu Y, et al. SNF2H promotes hepatocellular carcinoma proliferation by activating the Wnt/β-catenin signaling pathway. Oncol Lett. 2016;12:1329–36.PubMedPubMedCentralCrossRef
44.
Stopka T, Zakova D, Fuchs O, Kubrova O, Blafkova J, Jelinek J, et al. Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. Leukemia. 2000;14:1247–52.PubMedCrossRef
45.
Dluhosova M, Curik N, Vargova J, Jonasova A, Zikmund T, Stopka T. Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5. PLoS One. 2014;9:e87448.PubMedPubMedCentralCrossRef
46.
Sumegi J, Nishio J, Nelson M, Frayer RW, Perry D, Bridge JA. A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. Mod Pathol. 2011;24:333–42.PubMedCrossRef
47.
48.
Sheu JJ-C, Guan B, Choi J-H, Lin A, Lee C-H, Hsiao Y-T, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 2010;285:38260–9.PubMedPubMedCentralCrossRef
49.
Min S, Choi YW, Yun H, Jo S, Ji JH, Cho H. Post-translational regulation of the RSF1 chromatin remodeler under DNA damage. Mol Cells. 2018;41:127–33.PubMedPubMedCentral
50.
Choi JH, Sheu JJ-C, Guan B, Jinawath N, Markowski P, Wang T-L, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69:1407–15.PubMedPubMedCentralCrossRef
51.
He J, Fu L, Li Q. Rsf-1 regulates malignant melanoma cell viability and chemoresistance via NF-κB/Bcl-2 signaling. Mol Med Rep. 2019;20:3487–98.PubMedPubMedCentral
52.
Zhang X, Fu L, Xue D, Zhang X, Hao F, Xie L, et al. Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer. Virchows Arch. 2017;470:553–60.PubMedCrossRef
53.
Tai H-C, Huang H-Y, Lee S-W, Lin C-Y, Sheu M-J, Chang S-L, et al. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol. 2012;65:248–53.PubMedCrossRef
54.
Wu D, Nie X, Ma C, Liu X, Liang X, An Y, et al. RSF1 functions as an oncogene in osteosarcoma and is regulated by XIST/miR-193a-3p axis. Biomed Pharmacother. 2017;95:207–14.PubMedCrossRef
55.
Zhao X-C, An P, Wu X-Y, Zhang L-M, Long B, Tian Y, et al. Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1. Tumour Biol. 2016;37:7203–12.PubMedCrossRef
56.
Yang Y-I, Ahn J-H, Lee K-T, Shih I-M, Choi J-H. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res. 2014;74:2258–69.PubMedPubMedCentralCrossRef
57.
Chen X, Sun X, Guan J, Gai J, Xing J, Fu L, et al. Rsf-1 influences the sensitivity of non-small cell lung cancer to paclitaxel by regulating NF-κB pathway and its downstream proteins. Cell Physiol Biochem. 2017;44:2322–36.PubMedCrossRef
58.
Kshirsagar M, Jiang W, Shih I-M. DNA damage response is prominent in ovarian high-grade serous carcinomas, especially those with Rsf-1 (HBXAP) overexpression. J Oncol. 2012;2012:621685.PubMedCrossRef
59.
Sheu JJ-C, Choi JH, Guan B, Tsai F-J, Hua C-H, Lai M-T, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 2013;229:559–68.PubMedPubMedCentralCrossRef
60.
Sehdev AS, Kurman RJ, Kuhn E, Shih I-M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010;23:844–55.PubMedPubMedCentralCrossRef
61.
Ito T, Levenstein ME, Fyodorov DV, Kutach AK, Kobayashi R, Kadonaga JT. ACF consists of two subunits, Acf1 and ISWI, that function cooperatively in the ATP-dependent catalysis of chromatin assembly. Genes Dev. 1999;13:1529–39.PubMedPubMedCentralCrossRef
62.
Lan L, Ui A, Nakajima S, Hatakeyama K, Hoshi M, Watanabe R, et al. The ACF1 complex is required for DNA double-strand break repair in human cells. Mol Cell. 2010;40:976–87.PubMedCrossRef
63.
Kukimoto I, Elderkin S, Grimaldi M, Oelgeschläger T, Varga-Weisz PD. The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. Mol Cell. 2004;13:265–77.PubMedCrossRef
64.
Li X, Ding D, Yao J, Zhou B, Shen T, Qi Y, et al. Chromatin remodeling factor BAZ1A regulates cellular senescence in both cancer and normal cells. Life Sci. 2019;229:225–32.PubMedCrossRef
65.
Mahmood SF, Gruel N, Chapeaublanc E, Lescure A, Jones T, Reyal F, et al. A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis. 2014;35:670–82.PubMedCrossRef
66.
Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, et al. Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a resensitizing agent. Clin Cancer Res. 2018;24:3755–66.PubMedCrossRef
67.
Su D, Feng X, Colic M, Wang Y, Zhang C, Wang C, et al. CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions. DNA Repair. 2020;87:102803.PubMedPubMedCentralCrossRef
68.
Lu X, Meng X, Morris CA, Keating MT. A novel human gene, WSTF, is deleted in Williams syndrome. Genomics. 1998;54:241–9.PubMedCrossRef
69.
Liu Y, Zhang YY, Wang SQ, Li M, Long YH, Li YF, et al. WSTF acetylation by MOF promotes WSTF activities and oncogenic functions. Oncogene. 2020;39:5056–67.PubMedCrossRef
70.
Lundqvist J, Kirkegaard T, Laenkholm A-V, Duun-Henriksen AK, Bak M, Feldman D, et al. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D(3). J Steroid Biochem Mol Biol. 2018;177:171–8.PubMedCrossRef
71.
Lundqvist J, Hansen SK, Lykkesfeldt AE. Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase. Biochim Biophys Acta. 1833;2013:40–7.
72.
Meng J, Zhang X-T, Liu X-L, Fan L, Li C, Sun Y, et al. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal. 2016;28:1673–82.PubMedCrossRef
73.
Liu Y, Wang S-Q, Long Y-H, Chen S, Li Y-F, Zhang J-H. KRASG12 mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway. Oncotarget. 2016;7:53153–64.PubMedPubMedCentralCrossRef
74.
Hennig EE, Mikula M, Rubel T, Dadlez M, Ostrowski J. Comparative kinome analysis to identify putative colon tumor biomarkers. J Mol Med (Berlin, Germany). 2012;90:447–56.CrossRef
75.
Zhu YX, Tiedemann R, Shi C-X, Yin H, Schmidt JE, Bruins LA, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011;117:3847–57.PubMedPubMedCentralCrossRef
76.
Yang S, Quaresma AJC, Nickerson JA, Green KM, Shaffer SA, Imbalzano AN, et al. Subnuclear domain proteins in cancer cells support the functions of RUNX2 in the DNA damage response. J Cell Sci. 2015;128:728–40.PubMedPubMedCentral
77.
Y-j Z, Lu C-r, Cao Y, Luo Y, Bao R-f, Yan S, et al. Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway. Acta Pharmacol Sin. 2012;33:551–7.CrossRef
78.
Dong C, Sun J, Ma S, Zhang G. K-ras-ERK1/2 down-regulates H2A.X(Y142ph) through WSTF to promote the progress of gastric cancer. BMC Cancer. 2019;19:530.PubMedPubMedCentralCrossRef
79.
Tallant C, Valentini E, Fedorov O, Overvoorde L, Ferguson FM, Filippakopoulos P, et al. Molecular basis of histone tail recognition by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex NoRC. Structure. 2015;23:80–92.PubMedPubMedCentralCrossRef
80.
Anosova I, Melnik S, Tripsianes K, Kateb F, Grummt I, Sattler M. A novel RNA binding surface of the TAM domain of TIP5/BAZ2A mediates epigenetic regulation of rRNA genes. Nucleic Acids Res. 2015;43:5208–20.PubMedPubMedCentralCrossRef
81.
Paredes S, Angulo-Ibanez M, Tasselli L, Carlson SM, Zheng W, Li T-M, et al. The epigenetic regulator SIRT7 guards against mammalian cellular senescence induced by ribosomal DNA instability. J Biol Chem. 2018;293:11242–50.PubMedPubMedCentralCrossRef
82.
83.
Li C, Wu W, Ding H, Li Q, Xie K. The transcription factor 7 like 2-binding protein TIP5 activates β-catenin/transcription factor signaling in hepatocellular carcinoma. Mol Med Rep. 2018;17:7645–51.PubMedPubMedCentral
84.
Hanlon K, Rudin CE, Harries LW. Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One. 2009;4:e7169.PubMedPubMedCentralCrossRef
85.
Santoro R, Li J, Grummt I. The nucleolar remodeling complex NoRC mediates heterochromatin formation and silencing of ribosomal gene transcription. Nat Genet. 2002;32:393–6.PubMedCrossRef
86.
Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22:51–65.PubMedPubMedCentralCrossRef
87.
Guetg C, Scheifele F, Rosenthal F, Hottiger MO, Santoro R. Inheritance of silent rDNA chromatin is mediated by PARP1 via noncoding RNA. Mol Cell. 2012;45:790–800.PubMedCrossRef
88.
Panagopoulos I, Strömbeck B, Isaksson M, Heldrup J, Olofsson T, Johansson B. Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol. 2006;133:270–5.PubMedCrossRef
89.
Pietrzak K, Kuzyakiv R, Simon R, Bolis M, Bär D, Aprigliano R, et al. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN-loss. Proc Natl Acad Sci U S A. 2020;117:3637–47.PubMedPubMedCentralCrossRef
90.
91.
Elliott J, Norton KA, Niri FH, McDermid HE. Reported DNA repair protein CECR2, which is associated with neural tube defects in mice, is not required for double-strand break repair in primary neurospheres. DNA Repair (Amst). 2020;94:102876.CrossRef
92.
Lee SK, Park EJ, Lee HS, Lee YS, Kwon J. Genome-wide screen of human bromodomain-containing proteins identifies Cecr2 as a novel DNA damage response protein. Mol Cells. 2012;34:85–91.PubMedPubMedCentralCrossRef
93.
Zhang Y, Zhu J. Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma. Oncol Rep. 2019;41:908–16.PubMed
94.
95.
96.
Balboula AZ, Schultz RM. RBBP4 and RBBP7 regulate histone deacetylation during oocyte maturation in mouse. Biol Reprod. 2012;87:306.CrossRef
97.
Sant DW, Tao W, Field MG, Pelaez D, Jin K, Capobianco A, et al. Whole exome sequencing of lacrimal gland adenoid cystic carcinoma. Invest Ophthalmol Vis Sci. 2017;58:BIO240–6.PubMedPubMedCentralCrossRef
98.
Roussy M, Bilodeau M, Jouan L, Tibout P, Laramée L, Lemyre E, et al. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Genes, Chromosomes Cancer. 2018;57:311–9.PubMedCrossRef
99.
Richart L, Carrillo-de Santa Pau E, Río-Machín A, de Andrés MP, Cigudosa JC, VJS-A L, et al. BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. Nat Commun. 2016;7:10153.PubMedPubMedCentralCrossRef
100.
101.
Green AL, DeSisto J, Flannery P, Lemma R, Knox A, Lemieux M, et al. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020;39:2305–27.PubMedCrossRef
102.
Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Márquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 2013;45:1464–9.PubMedPubMedCentralCrossRef
103.
Kim K, Punj V, Choi J, Heo K, Kim J-M, Laird PW, et al. Gene dysregulation by histone variant H2A.Z in bladder cancer. Epigenetics Chromatin. 2013;6:34.PubMedPubMedCentralCrossRef
104.
Richart L, Felipe I, Delgado P, Andrés MP, Prieto J, Pozo ND, et al. Bptf determines oncogenic addiction in aggressive B-cell lymphomas. Oncogene. 2020;39:4884–95.PubMedCrossRef
105.
Li HJ, Yu PN, Huang KY, Su HY, Hsiao TH, Chang CP, et al. NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition. Oncogene. 2016;35:2266–78.PubMedCrossRef
106.
Li M, Aliotta JM, Asara JM, Wu Q, Dooner MS, Tucker LD, et al. Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture. J Biol Chem. 2010;285:6285–97.PubMedCrossRef
107.
Wang J, He C, Gao P, Wang S, Lv R, Zhou H, et al. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer. Oncogene. 2020;39:1335–46.PubMedCrossRef
108.
Fu J, Qin L, He T, Qin J, Hong J, Wong J, et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 2011;21:275–89.PubMedCrossRef
109.
Kitange GJ, Mladek AC, Schroeder MA, Pokorny JC, Carlson BL, Zhang Y, et al. Retinoblastoma binding protein 4 modulates temozolomide sensitivity in glioblastoma by regulating DNA repair proteins. Cell Rep. 2016;14:2587–98.PubMedPubMedCentralCrossRef
110.
Moody RR, Lo M-C, Meagher JL, Lin C-C, Stevers NO, Tinsley SL, et al. Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem. 2018;293:2125–36.PubMedCrossRef
111.
Liu BH, Jobichen C, Chia CSB, Chan THM, Tang JP, Chung TXY, et al. Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide. Proc Natl Acad Sci U S A. 2018;115:E7119–28.PubMedPubMedCentralCrossRef
112.
Li D, Song H, Mei H, Fang E, Wang X, Yang F, et al. Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4. Nat Commun. 2018;9:2829.PubMedPubMedCentralCrossRef
113.
Dar AA, Majid S, Bezrookove V, Phan B, Ursu S, Nosrati M, et al. BPTF transduces MITF-driven prosurvival signals in melanoma cells. Proc Natl Acad Sci U S A. 2016;113:6254–8.PubMedPubMedCentralCrossRef
114.
Koludrovic D, Laurette P, Strub T, Keime C, Le Coz M, Coassolo S, et al. Chromatin-Remodelling complex NURF is essential for differentiation of adult melanocyte stem cells. PLoS Genet. 2015;11:e1005555.PubMedPubMedCentralCrossRef
115.
Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu X, et al. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4. Mol Cancer. 2019;18:45.PubMedPubMedCentralCrossRef
116.
117.
Shao M, Yang Q, Zhu W, Jin H, Wang J, Song J, et al. LncHOXA10 drives liver TICs self-renewal and tumorigenesis via HOXA10 transcription activation. Mol Cancer. 2018;17:173.PubMedPubMedCentralCrossRef
118.
Zhu P, Wu J, Wang Y, Zhu X, Lu T, Liu B, et al. LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis. Nat Cell Biol. 2018;20:1134–44.PubMedCrossRef
119.
Glancy E, Ciferri C, Bracken AP. Structural basis for PRC2 engagement with chromatin. Curr Opin Struct Biol. 2021;67:135–44.PubMedCrossRef
120.
Dirscherl SS, Krebs JE. Functional diversity of ISWI complexes. Biochem Cell Biol. 2004;82:482–9.PubMedCrossRef
121.
Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev. 1996;10:2117–30.PubMedCrossRef
122.
Emelyanov AV, Vershilova E, Ignatyeva MA, Pokrovsky DK, Lu X, Konev AY, et al. Identification and characterization of ToRC, a novel ISWI-containing ATP-dependent chromatin assembly complex. Genes Dev. 2012;26:603–14.PubMedPubMedCentralCrossRef
123.
Arumugam K, Shin W, Schiavone V, Vlahos L, Tu X, Carnevali D, et al. The master regulator protein BAZ2B can reprogram human hematopoietic lineage-committed progenitors into a multipotent state. Cell Rep. 2020;33:108474.PubMedPubMedCentralCrossRef
124.
Liu F, Tai Y, Ma J. LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther. 2018;19:534–42.PubMedPubMedCentralCrossRef
125.
Li Y, Li J, Luo M, Zhou C, Shi X, Yang W, et al. Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. Cancer Lett. 2018;430:57–66.PubMedCrossRef
126.
Kong Z, Wan X, Zhang Y, Zhang P, Zhang Y, Zhang X, et al. Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2017;493:1217–23.PubMedCrossRef
127.
Yu J, Xu Q-G, Wang Z-G, Yang Y, Zhang L, Ma J-Z, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214–27.PubMedCrossRef
128.
Liu Q, Cai Y, Xiong H, Deng Y, Dai X. CCRDB: a cancer circRNAs-related database and its application in hepatocellular carcinoma-related circRNAs. Database. 2019;2019:baz063.PubMedPubMedCentralCrossRef
129.
Bi J, Liu H, Cai Z, Dong W, Jiang N, Yang M, et al. Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis. Aging. 2018;10:1964–76.PubMedPubMedCentralCrossRef
130.
Landry JW, Banerjee S, Taylor B, Aplan PD, Singer A, Wu C. Chromatin remodeling complex NURF regulates thymocyte maturation. Genes Dev. 2011;25:275–86.PubMedPubMedCentralCrossRef
131.
Mayes K, Alkhatib SG, Peterson K, Alhazmi A, Song C, Chan V, et al. BPTF depletion enhances T-cell-mediated antitumor immunity. Cancer Res. 2016;76:6183–92.PubMedPubMedCentralCrossRef
132.
Peterson K. Investigating the role of Bptf in Immunoediting in breast cancer and melanoma; 2015.
133.
Wu B, Wang Y, Wang C, Wang GG, Wu J, Wan YY. BPTF is essential for T cell homeostasis and function. J Immunol. 2016;197:4325–33.PubMedCrossRef
134.
Siamishi I, Iwanami N, Clapes T, Trompouki E, O'Meara CP, Boehm T. Lymphocyte-specific function of the DNA polymerase epsilon subunit Pole3 revealed by neomorphic alleles. Cell Rep. 2020;31:107756.PubMedCrossRef
135.
Sun L, Kong B, Sheng X, Sheu JJ, Shih Ie M. Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. Biochem Biophys Res Commun. 2010;394:633–8.PubMedCrossRef
136.
Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829-842.e813.CrossRef
137.
Wu D. Innate and adaptive immune cell metabolism in tumor microenvironment. Adv Exp Med Biol. 2017;1011:211–23.PubMedCrossRef
138.
139.
Zhang M, Liu Z, Aoshima K, An Y, Aoshima A, Chan L, Lang S, Sun H, Rutter S, Booth C, et al: CECR2 drives breast cancer metastasis by suppressing macrophage inflammatory responses.2020.CrossRef
140.
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.PubMedPubMedCentralCrossRef
141.
Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12:323–39.PubMedCrossRef
142.
Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, et al. GSK2801, a BAZ2/BRD9 Bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Mol Cancer Res. 2019;17:1503–18.PubMedPubMedCentralCrossRef
143.
Frey WD, Chaudhry A, Slepicka PF, Ouellette AM, Kirberger SE, Pomerantz WCK, et al. BPTF maintains chromatin accessibility and the self-renewal capacity of mammary gland stem cells. Stem cell reports. 2017;9:23–31.PubMedPubMedCentralCrossRef
144.
Grüne T, Brzeski J, Eberharter A, Clapier CR, Corona DFV, Becker PB, et al. Crystal structure and functional analysis of a nucleosome recognition module of the remodeling factor ISWI. Mol Cell. 2003;12:449–60.PubMedCrossRef
145.
Yamada K, Frouws TD, Angst B, Fitzgerald DJ, DeLuca C, Schimmele K, et al. Structure and mechanism of the chromatin remodelling factor ISW1a. Nature. 2011;472:448–53.PubMedCrossRef
146.
Harrer N, Schindler CEM, Bruetzel LK, Forné I, Ludwigsen J, Imhof A, et al. Structural architecture of the nucleosome remodeler ISWI determined from cross-linking, mass spectrometry, SAXS, and modeling. Structure. 2018;26:282–294.e6.
147.
Yan L, Wu H, Li X, Gao N, Chen Z. Structures of the ISWI-nucleosome complex reveal a conserved mechanism of chromatin remodeling. Nat Struct Mol Biol. 2019;26:258–66.PubMedCrossRef
148.
Yan L, Wang L, Tian Y, Xia X, Chen Z. Structure and regulation of the chromatin remodeller ISWI. Nature. 2016;540:466–9.PubMedCrossRef
149.
Chittori S, Hong J, Bai Y, Subramaniam S. Structure of the primed state of the ATPase domain of chromatin remodeling factor ISWI bound to the nucleosome. Nucleic Acids Res. 2019;47:9400–9.PubMedPubMedCentralCrossRef
150.
Armache JP, Gamarra N, Johnson SL, Leonard JD, Wu S, Narlikar GJ, et al. Cryo-EM structures of remodeler-nucleosome intermediates suggest allosteric control through the nucleosome. eLife. 2019;8:e46057.
Metadata
Title
The emerging role of ISWI chromatin remodeling complexes in cancer
Authors
Yanan Li
Han Gong
Pan Wang
Yu Zhu
Hongling Peng
Yajuan Cui
Heng Li
Jing Liu
Zi Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02151-x

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Research

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Correction

Correction to: Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity

Research

Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease

Review

SCD1, autophagy and cancer: implications for therapy

Research

Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression

Research

Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits